ATHEROSCLEROSIS
Abstract
When cardiovascular risk factors (e.g., chemical, mechanical, or immunological insults) cause
and injure your endothelium and contribute to its dysfunction and fragmentation, atherosclerosis
begins. A cascade of inflammatory responses then takes place, involving monocytes,
macrophages, T lymphocytes, and vascular smooth muscle (VSC) cells. In particular,
atherosclerosis lesions have been observed to have increased levels of T helper (helper)1 (HL1)
cells along with elevated levels of the pro-inflammatory (HL1) helper (HL1) related cytokines.
In addition to pro-inflammatory cytokines, many other molecular factors play a role in
atherosclerosis's appearance, progression, and complications, including chemokines and growth
factors, vasoactive agents, enzymes, and apoptosis signals (apoptosis signals). Many of these
molecules play a role in both the activity and burden of the disease, but they may also play an
essential role in its pathogenesis.
Keywords: arteries, atherosclerosis, disease, enzymes, plaque, progression,
Introduction
The accumulation of fats, cholesterol, and other materials on the artery walls is thought to
cause atherosclerosis. The collection known as plaque has the potential to narrow the arteries and
impede blood flow. Plaque can rupture and result in the formation of blood clots.
Atherosclerosis, commonly called extensive artery disease, is a chronic disease caused by the
accumulation of oxidized lipids on the artery wall, neointima formation, fibrous cap formation,
and inflammatory cell migration onto damaged endothelial cells. Dyslipidemia is one of the main
risk factors for atherosclerosis. It may suppress the expression of Vascular Cell Adhesion
2
ATHEROSCLEROSIS
Molecule-1, Intercellular Adhesion Molecules-1, and E-Selectin, adhesion molecules induced by
lipopolysaccharides. 1
Symptoms related to other heart problems are caused by atherosclerosis, a degenerative
disease of the arteries that reduces blood flow to the heart. A blood clot that forms when a plaque
bursts may completely block the street or spread to other body parts.1 Complications like heart
attack, stroke, vascular dementia, erectile dysfunction, or limb loss can result from full or partial
blockages—atherosclerosis results in impairment and death. 2Alpha-tocopherol (tocopherol),
phytosterols, alcohols derived from triterpenes, unsaturated fatty acids, and tocotrienols (OTC)
are the main ingredients of this medication.2 This medication enhances the plasma lipid profile in
humans, non-human primates, rabbits, and rodents. It raises HDL-C (high-density lipoprotein
cholesterol) and lowers total plasma cholesterol (TSC) and triglyceride concentration (TLD
cholesterol).3
However, the complexity of the disease's aetiology has hampered efforts to define the
cellular and molecular interactions involved. In the last ten years, the development of novel
research instruments, such as genetically engineered mice models of disease, has led to a better
comprehension of the molecular pathways linking modified cholesterol metabolism and
additional risk factors to the formation of atherosclerotic plaque.3 It is now evident that
atherosclerosis is a chronic inflammatory condition that can be transformed into an acute clinical
event by plaque rupture and thrombosis, rather than just an unavoidable degenerative
consequence of aging.4
3
ATHEROSCLEROSIS
Conclusion
Even though atherosclerosis is frequently associated with heart issues, it can affect
arteries anywhere in the body. One can treat atherosclerosis. Atherosclerosis can be avoided by
adopting healthy lifestyle practices. Atherosclerosis is the result of several highly specialized
cellular and molecular reactions. 4 There are key molecular signals play a significant role in
regulating the multi-step process of vascular injury under cardiovascular risk exposure, vascular
cell senescence and apoptosis, and the contribution of progenitor cells to vascular repair.5
Interventional cardiovascular medicine may benefit from applying this molecular knowledge to a
more thorough understanding of the complex regulation of atherosclerosis development and
progression to better the clinical outcomes that coincide with the complication of susceptible
atherosclerotic plaques.5
PLACEHOLDER.1
References
1. Pahwa R, Jialal I. Atherosclerosis. [Updated 2023 Aug 8]. In: StatPearls [Internet]. Treasure
Island (FL): StatPearls Publishing; 2024 Jan-. Available from:
https://www.ncbi.nlm.nih.gov/books/NBK507799/.
2. Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I,
4
ATHEROSCLEROSIS
Vandenbroeck K, Benito-Vicente A, Martín C. Pathophysiology of Atherosclerosis. Int J Mol
Sci. 2022 Mar 20;23(6):3346. doi: 10.3390/ijms23063346. PMID: 35328769; PMCID:
PMC8954705.
3. Lusis AJ. Atherosclerosis. Nature. 2000 Sep 14;407(6801):233-41. doi: 10.1038/35025203.
PMID: 11001066; PMCID: PMC2826222.
4. Rafieian-Kopaei M, Setorki M, Doudi M, Baradaran A, Nasri H. Atherosclerosis: process,
indicators, risk factors and new hopes. Int J Prev Med. 2014 Aug;5(8):927-46. PMID:
25489440; PMCID: PMC4258672.
5. Vasan RS, Pan S, Larson MG, Mitchell GF, Xanthakis V. Arteriosclerosis, Atherosclerosis,
and Cardiovascular Health: Joint Relations to the Incidence of Cardiovascular Disease.
Hypertension. 2021 Nov;78(5):1232-1240. doi: 10.1161/HYPERTENSIONAHA.121.18075.
Epub 2021 Oct 4. PMID: 34601961; PMCID: PMC8516717.
Appendix
"Add content here or delete this page if not needed"
5
Powered by TCPDF (www.tcpdf.org)
